UBS Group AG Has $2.56 Million Holdings in Zevra Therapeutics, Inc. $ZVRA

UBS Group AG boosted its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 30.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 285,488 shares of the company’s stock after purchasing an additional 67,392 shares during the period. UBS Group AG owned about 0.51% of Zevra Therapeutics worth $2,558,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC increased its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning acquired a new stake in Zevra Therapeutics in the second quarter valued at $92,000. Qube Research & Technologies Ltd acquired a new stake in Zevra Therapeutics in the second quarter valued at $99,000. Finally, Quarry LP acquired a new stake in Zevra Therapeutics in the third quarter valued at $103,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Trading Up 2.9%

Shares of Zevra Therapeutics stock opened at $10.32 on Wednesday. The business has a 50-day moving average price of $10.05 and a two-hundred day moving average price of $9.26. Zevra Therapeutics, Inc. has a 1-year low of $7.16 and a 1-year high of $13.16. The company has a market cap of $610.07 million, a P/E ratio of 5.19 and a beta of 0.88.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The firm had revenue of $36.22 million during the quarter, compared to the consensus estimate of $31.96 million. Equities research analysts forecast that Zevra Therapeutics, Inc. will post 0.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ZVRA shares. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, April 11th. BTIG Research started coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 price objective for the company. Guggenheim increased their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings downgraded Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Friday. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.